APVO
Aptevo Therapeutics Inc.
Price Chart
Latest Quote
$4.72
-0.27 (-5.41%)
Current Price
| Previous Close | $4.99 |
| Open | $5.03 |
| Day High | $5.03 |
| Day Low | $4.71 |
| Volume | 27,635 |
Stock Information
| Shares Outstanding | 1.25M |
| Total Debt | $4.42M |
| Cash Equivalents | $14.53M |
| Net Income | $-26.16M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.88M |
| P/E Ratio | 0.00 |
| EPS (TTM) | $1488.13 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-4.22M |
| Income | $-26.16M |
| Book/sh | $9.65 |
| Cash/sh | $11.66 |
| Employees | 33 |
Financial Ratios
| Quick Ratio | 3.05 |
| Current Ratio | 3.36 |
| Debt/Eq | 38.08 |
Returns & Margins
| ROA | -118.03% |
| ROE | -517.92% |
Ownership
| Insider Ownership | 0.06% |
| Institutional Ownership | 4.47% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.22 |
| P/B | 0.49 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $21.00 |
Technical Indicators
| SMA20 | $4.87 |
| SMA50 | $4.81 |
| SMA200 | $15.14 |
| RSI | 48.93 |
| ATR | 0.3606 |
| Shares Float | 1.25M |
| Short Float | 7.05% |
| Short Ratio | 2.20 |
| Rel Volume | 0.77 |
Performance History
| Week | -3.87% |
| Month | -4.45% |
| Quarter | -26.25% |
| 6 Months | -81.00% |
| YTD | -49.73% |
| Year | -94.71% |
| 3 Years | -100.00% |
| 5 Years | -100.00% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $4.72 | 28,200 |
| 2026-06-04 | $5.08 | 38,500 |
| 2026-06-03 | $5.02 | 118,200 |
| 2026-06-02 | $5.04 | 98,400 |
| 2026-06-01 | $5.24 | 41,000 |
| 2026-05-29 | $4.91 | 20,700 |
| 2026-05-28 | $5.00 | 62,500 |
| 2026-05-27 | $4.84 | 90,600 |
| 2026-05-26 | $4.89 | 20,500 |
| 2026-05-22 | $4.95 | 26,600 |
| 2026-05-21 | $5.04 | 17,200 |
| 2026-05-20 | $4.55 | 17,400 |
| 2026-05-19 | $4.45 | 10,900 |
| 2026-05-18 | $4.63 | 10,100 |
| 2026-05-15 | $4.77 | 11,700 |
| 2026-05-14 | $4.80 | 27,200 |
| 2026-05-13 | $4.76 | 17,900 |
| 2026-05-12 | $4.83 | 10,900 |
| 2026-05-11 | $4.84 | 28,800 |
| 2026-05-08 | $4.97 | 32,600 |
| 2026-05-07 | $4.86 | 28,700 |
| 2026-05-06 | $4.94 | 462,700 |
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment malignant pleural mesothelioma, non-small cell lung, gastric/gastro-esophageal, head and neck squamous cell carcinoma, pancreatic, renal, ovarian, prostate, breast, cervical, colorectal, endometrial, and bladder cancers; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
đ° Latest News
All You Need to Know About Aptevo Therapeutics (APVO) Rating Upgrade to Buy
Zacks âĸ 2026-05-20T16:00:04Z
Aptevo Therapeutics (APVO) Upgraded to Buy: Here's Why
Zacks âĸ 2026-04-10T16:00:02Z
Sector Update: Health Care Stocks Edge Higher Late Afternoon
MT Newswires âĸ 2025-12-26T21:06:46ZAptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Zacks âĸ 2025-11-19T14:55:01Z
Wall Street Set to Open Higher Thursday; Jobless Claims Fall as Manufacturing Index Rebounds
MT Newswires âĸ 2025-09-18T13:27:56ZAptevo Meets Nasdaq $2.5M Equity Requirement
Insider Monkey âĸ 2025-07-15T20:57:06Z
Aptevo announces addition of preclinical candidate APVO455 to portfolio
TipRanks âĸ 2025-06-21T13:00:57Z
Aptevo Therapeutics Launches $8 Million Offering
MT Newswires âĸ 2025-06-18T15:35:28Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $3,114,000 |
| Operating Revenue | $0 | $0 | $0 | $3,114,000 |
| Expenses | ||||
| Total Expenses | $26,312,000 | $24,602,000 | $28,878,000 | $31,755,000 |
| Other Income Expense | $345,000 | $472,000 | $10,228,000 | $35,655,000 |
| Other Non Operating Income Expenses | $345,000 | $472,000 | $578,000 | $35,655,000 |
| Operating Expense | $26,312,000 | $24,602,000 | $28,878,000 | $31,755,000 |
| General And Administrative Expense | $11,772,000 | $10,224,000 | $11,771,000 | $13,873,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-25,967,000 | $-24,130,000 | $-18,650,000 | $7,014,000 |
| Normalized Income | $-25,967,000 | $-24,130,000 | $-28,300,000 | $7,014,000 |
| Net Income From Continuing And Discontinued Operation | $-25,967,000 | $-24,130,000 | $-17,411,000 | $8,027,000 |
| Total Operating Income As Reported | $-26,312,000 | $-24,602,000 | $-28,878,000 | $-28,641,000 |
| Net Income Common Stockholders | $-27,538,000 | $-24,130,000 | $-17,411,000 | $8,027,000 |
| Net Income | $-25,967,000 | $-24,130,000 | $-17,411,000 | $8,027,000 |
| Net Income Including Noncontrolling Interests | $-25,967,000 | $-24,130,000 | $-17,411,000 | $8,027,000 |
| Net Income Continuous Operations | $-25,967,000 | $-24,130,000 | $-18,650,000 | $7,014,000 |
| Pretax Income | $-25,967,000 | $-24,130,000 | $-18,650,000 | $7,014,000 |
| Operating Income | $-26,312,000 | $-24,602,000 | $-28,878,000 | $-28,641,000 |
| Net Income Discontinuous Operations | - | $0 | $1,239,000 | $1,013,000 |
| Special Income Charges | - | $0 | $9,650,000 | $0 |
| Per Share | ||||
| Diluted EPS | $-87.27 | $-31460.23 | $-527606.06 | $729727.27 |
| Basic EPS | $-87.27 | $-5956.55 | $-527606.06 | $729727.27 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-26,072,000 | $-24,250,000 | $-37,961,000 | $-27,740,000 |
| Reconciled Depreciation | $240,000 | $352,000 | $567,000 | $901,000 |
| EBITDA (Bullshit earnings) | $-26,072,000 | $-24,250,000 | $-28,311,000 | $-27,740,000 |
| EBIT | $-26,312,000 | $-24,602,000 | $-28,878,000 | $-28,641,000 |
| Diluted Average Shares | $315,535 | $4,051 | $33 | $11 |
| Basic Average Shares | $315,535 | $4,051 | $33 | $11 |
| Diluted NI Availto Com Stockholders | $-27,538,000 | $-24,130,000 | $-17,411,000 | $8,027,000 |
| Otherunder Preferred Stock Dividend | $1,571,000 | $0 | - | - |
| Research And Development | $14,540,000 | $14,378,000 | $17,107,000 | $17,882,000 |
| Selling General And Administration | $11,772,000 | $10,224,000 | $11,771,000 | $13,873,000 |
| Other Gand A | $11,772,000 | $10,224,000 | $11,771,000 | $13,873,000 |
| Total Unusual Items | - | $0 | $9,650,000 | $0 |
| Total Unusual Items Excluding Goodwill | - | $0 | $9,650,000 | $0 |
| Gain On Sale Of Ppe | - | $0 | $9,650,000 | $0 |
| Other Special Charges | - | - | - | $-37,182,000 |
Fetched: 2026-06-06
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $17,381,000 | $4,755,000 | $12,221,000 | $17,974,000 |
| Total Assets | $27,194,000 | $15,591,000 | $24,842,000 | $34,215,000 |
| Total Non Current Assets | $4,113,000 | $4,932,000 | $5,776,000 | $6,765,000 |
| Current Assets | $23,081,000 | $10,659,000 | $19,066,000 | $27,450,000 |
| Other Current Assets | $1,462,000 | $1,945,000 | $689,000 | $744,000 |
| Cash Cash Equivalents And Short Term Investments | $21,619,000 | $8,714,000 | $16,904,000 | $22,635,000 |
| Cash And Cash Equivalents | $21,619,000 | $8,714,000 | $16,904,000 | $22,635,000 |
| Cash Equivalents | $20,496,000 | $7,533,000 | $13,171,000 | $21,569,000 |
| Cash Financial | $1,123,000 | $1,181,000 | $3,733,000 | $1,066,000 |
| Prepaid Assets | - | $1,689,000 | $1,473,000 | $1,571,000 |
| Receivables | - | - | $0 | $2,500,000 |
| Restricted Cash | - | - | - | $0 |
| Other Receivables | - | - | - | $2,500,000 |
| Other Non Current Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $4,629,000 | $5,397,000 | $5,397,000 | $9,535,000 |
| Long Term Debt And Capital Lease Obligation | $3,763,000 | $4,629,000 | $5,397,000 | $7,535,000 |
| Current Debt And Capital Lease Obligation | $866,000 | $768,000 | - | $2,000,000 |
| Long Term Debt | - | - | - | $1,456,000 |
| Current Debt | - | - | - | $2,000,000 |
| Other Current Borrowings | - | - | - | $2,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $9,813,000 | $10,836,000 | $12,621,000 | $16,241,000 |
| Total Non Current Liabilities Net Minority Interest | $3,763,000 | $4,629,000 | $5,397,000 | $7,535,000 |
| Current Liabilities | $6,050,000 | $6,207,000 | $7,224,000 | $8,706,000 |
| Payables And Accrued Expenses | $5,184,000 | $5,439,000 | $3,984,000 | $3,499,000 |
| Payables | $877,000 | $1,242,000 | - | - |
| Accounts Payable | $877,000 | $1,242,000 | - | - |
| Other Current Liabilities | - | $1,298,000 | $1,142,000 | $1,102,000 |
| Other Non Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $17,381,000 | $4,755,000 | $12,221,000 | $17,974,000 |
| Total Equity Gross Minority Interest | $17,381,000 | $4,755,000 | $12,221,000 | $17,974,000 |
| Stockholders Equity | $17,381,000 | $4,755,000 | $12,221,000 | $17,974,000 |
| Retained Earnings | $-275,115,000 | $-247,577,000 | $-223,447,000 | $-206,036,000 |
| Other | ||||
| Ordinary Shares Number | $997,830 | $4,051 | $33 | $11 |
| Share Issued | $997,830 | $4,051 | $33 | $11 |
| Tangible Book Value | $17,381,000 | $4,755,000 | $12,221,000 | $17,974,000 |
| Invested Capital | $17,381,000 | $4,755,000 | $12,221,000 | $21,430,000 |
| Working Capital | $17,031,000 | $4,452,000 | $11,842,000 | $18,744,000 |
| Capital Lease Obligations | $4,629,000 | $5,397,000 | $5,397,000 | $6,079,000 |
| Total Capitalization | $17,381,000 | $4,755,000 | $12,221,000 | $19,430,000 |
| Additional Paid In Capital | $292,382,000 | $252,248,000 | $235,607,000 | $223,962,000 |
| Capital Stock | $114,000 | $84,000 | $61,000 | $48,000 |
| Common Stock | $114,000 | $84,000 | $61,000 | $48,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $3,763,000 | $4,629,000 | $5,397,000 | $6,079,000 |
| Current Capital Lease Obligation | $866,000 | $768,000 | - | - |
| Current Accrued Expenses | $4,307,000 | $4,197,000 | - | - |
| Net PPE | $4,113,000 | $4,932,000 | $5,776,000 | $6,765,000 |
| Accumulated Depreciation | $-14,143,000 | $-13,945,000 | $-13,593,000 | $-13,026,000 |
| Gross PPE | $18,256,000 | $18,877,000 | $19,369,000 | $19,791,000 |
| Leases | $2,228,000 | $2,228,000 | $2,228,000 | $2,228,000 |
| Machinery Furniture Equipment | $12,218,000 | $12,260,000 | $12,260,000 | $12,260,000 |
| Buildings And Improvements | $3,810,000 | $4,389,000 | $4,881,000 | $5,303,000 |
| Properties | $0 | $0 | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | - | $1,856,000 | $2,098,000 | $2,105,000 |
| Treasury Shares Number | - | - | $0 | - |
| Other Properties | - | - | - | - |
Fetched: 2026-06-06
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-25,592,000 | $-23,785,000 | $-11,730,000 | $-21,051,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-25,592,000 | $-23,785,000 | $-11,730,000 | $-21,022,000 |
| Cash Flow From Continuing Operating Activities | $-25,592,000 | $-23,785,000 | $-11,730,000 | $-21,022,000 |
| Operating Gains Losses | - | - | - | $47,000 |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $0 | $0 | $-29,000 |
| Cash Flow From Continuing Investing Activities | - | - | $0 | $-29,000 |
| Capital Expenditure | - | - | - | $-29,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $37,940,000 | $10,036,000 | $6,428,000 | $6,934,000 |
| Financing Cash Flow | $38,497,000 | $15,595,000 | $5,998,000 | $-2,616,000 |
| Cash Flow From Continuing Financing Activities | $38,497,000 | $15,595,000 | $5,998,000 | $-2,616,000 |
| Net Common Stock Issuance | $37,940,000 | $10,036,000 | $6,428,000 | $6,934,000 |
| Common Stock Issuance | $37,940,000 | $10,036,000 | $6,428,000 | $6,934,000 |
| Net Other Financing Charges | - | $-4,000 | $-10,000 | $2,717,000 |
| Other | ||||
| End Cash Position | $21,619,000 | $8,714,000 | $16,904,000 | $22,636,000 |
| Beginning Cash Position | $8,714,000 | $16,904,000 | $22,636,000 | $46,303,000 |
| Changes In Cash | $12,905,000 | $-8,190,000 | $-5,732,000 | $-23,667,000 |
| Proceeds From Stock Option Exercised | $557,000 | $5,563,000 | $3,047,000 | $0 |
| Change In Working Capital | $-1,050,000 | $-2,176,000 | $2,911,000 | $2,144,000 |
| Change In Other Current Liabilities | $-1,376,000 | $-1,376,000 | $-682,000 | $366,000 |
| Change In Payables And Accrued Expense | $-157,000 | $-1,017,000 | $518,000 | $-394,000 |
| Change In Payable | $-157,000 | $-1,017,000 | $518,000 | $-394,000 |
| Change In Account Payable | $-157,000 | $-1,017,000 | $518,000 | $-394,000 |
| Change In Prepaid Assets | $483,000 | $217,000 | $153,000 | $355,000 |
| Other Non Cash Items | $1,089,000 | $1,100,000 | $10,000 | $-33,943,000 |
| Stock Based Compensation | $96,000 | $1,069,000 | $2,193,000 | $1,802,000 |
| Depreciation Amortization Depletion | $240,000 | $352,000 | $567,000 | $901,000 |
| Depreciation And Amortization | $240,000 | $352,000 | $567,000 | $901,000 |
| Net Income From Continuing Operations | $-25,967,000 | $-24,130,000 | $-17,411,000 | $8,027,000 |
| Repayment Of Debt | - | $0 | $-3,467,000 | $-12,267,000 |
| Net Issuance Payments Of Debt | - | $0 | $-3,467,000 | $-12,267,000 |
| Net Long Term Debt Issuance | - | $0 | $-3,467,000 | $-12,267,000 |
| Long Term Debt Payments | - | $0 | $-3,467,000 | $-12,267,000 |
| Change In Other Current Assets | - | $492,000 | $422,000 | $653,000 |
| Change In Receivables | - | $0 | $2,500,000 | $1,164,000 |
| Net PPE Purchase And Sale | - | - | $0 | $-29,000 |
| Purchase Of PPE | - | - | $0 | $-29,000 |
| Gain Loss On Sale Of PPE | - | - | $0 | $47,000 |
| Net Business Purchase And Sale | - | - | - | - |
| Sale Of Business | - | - | - | - |
| Gain Loss On Sale Of Business | - | - | - | - |
Fetched: 2026-06-06